Topics
Health
Pharma
Biotech
Politics & Policy
Health Tech
In the Lab
Business
Opinion
First Opinion
The Pharmalot View
Adam’s Take
Podcast
Video
Newsletters
Events
Upcoming Events
STAT Summit
Webinars
STAT Expert Advantage
Log in
Subscribe
Newsletters
Try STAT Plus
Newsletters
Try STAT Plus
Pfizer
Pharmalot
Pfizer sues Texas agency over releasing Medicaid data to lawmakers
By
Ed Silverman
Pharmalot
After a long battle, Pfizer drops the price of its Prevnar vaccine to humanitarian groups
By
Ed Silverman
advertisement
Pharmalot
Pharmalot, Pharmalittle: Pfizer may sell or spin off its consumer business
By
Ed Silverman
advertisement
Pharmalot
Up and down the ladder: The latest comings and goings
By
Ed Silverman
Pharmalot
Pfizer stops developing a cholesterol drug. So who is the big winner?
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Is the 21st Century Cures bill in doubt over drug prices?
By
Ed Silverman
Pharmalot
Pfizer fined again for violating environmental law at Puerto Rico plant
By
Ed Silverman
advertisement
Pharmalot
Interfaith investor coalition pushes shareholder resolutions on drug prices
By
Ed Silverman
advertisement
Pharmalot
Pharmalot, Pharmalittle: Chicago plans to require licenses for sales reps who market opioids
By
Ed Silverman
Pharmalot
Are concerns about a price war between Johnson & Johnson and Pfizer ‘overblown’?
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month
By
Ed Silverman
Pharmalot
Up and down the ladder: The latest comings and goings
By
Ed Silverman
Pharmalot
Doctors Without Borders chastises Pfizer for refusing to lower vaccine price
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: To avoid scandal, Novartis CEO advises companies not to hire rulebreakers
By
Ed Silverman
Pharmalot
Pfizer won’t split into two companies, so what’s next?
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Pfizer decides not to split into two companies
By
Ed Silverman
Pharmalot
FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill
By
Ed Silverman
Pharmalot
FDA reviewers question Pfizer study about safety of its Chantix smoking cessation pill
By
Ed Silverman
Pharmalot
Up and down the ladder: The latest comings and goings
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Pfizer CEO says Clinton drug pricing plan is ‘very negative’
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Are concerns about spending on orphan drugs overblown?
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Docs disciplined for misconduct still paid by pharma to be speakers, advisers
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: India wants you to know its drugs are safe and effective
By
Ed Silverman
Business
Pfizer buying Medivation in deal valued at about $14 billion
By
Associated Press
Pharmalot
Pharmalot, Pharmalittle: Pfizer pays $14 billion for Medivation and its prostate cancer drug
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing
By
Ed Silverman
Pharmalot
Pfizer closes plant in India after several regulators find problems
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Bristol-Myers cancer drug misses main goal in late-stage study
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Brexit, schmexit. Glaxo invests $360 million in the UK
By
Ed Silverman
Next Page »
